Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MPN Workshop of the Carolinas 2024 | Interferon in PV and ET: unanswered questions

Raajit Rampal • 24 Aug 2024
MPN Workshop of the Carolinas 2024
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Interferon

In this video, Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the use of interferon in polycythemia vera (PV) and essential thrombocythemia (ET) and introduces questions about their sequencing and potential use in lower-risk patients. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

MPN Channel VJHemOnc banner, with Claire Harrison, Ruben Mesa, Lucia Masarova, Naveen Pemmaraju

More from Raajit Rampal

MPN Progression Registry: insights into the work of the MPN Research Foundation
19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026
An update on combination strategies in frontline myelofibrosis
14:35
An update on combination strategies in frontline myelofibrosis
Nikolai Podoltsev et al. • 2 Oct 2026
The evolving treatment landscape in PV
0:56
The evolving treatment landscape in PV
Raajit Rampal • 24 Aug 2024
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models
1:27
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models
Raajit Rampal • 24 Aug 2024

Related Videos

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals